迪瑞医疗(300396) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥331,932,094.69, representing a 46.54% increase compared to ¥226,514,694.52 in the same period last year[5] - Net profit attributable to shareholders was ¥77,711,739.74, up 27.79% from ¥60,813,979.13 year-on-year[5] - The company achieved a basic earnings per share of ¥0.2865, reflecting a 29.17% increase from ¥0.2218 in the same period last year[5] - Total operating revenue for Q1 2023 reached ¥331,932,094.69, a significant increase of 46.6% compared to ¥226,514,694.52 in the same period last year[23] - Operating profit for Q1 2023 was ¥85,536,589.74, representing a 27.1% increase from ¥67,273,409.04 in the previous year[23] - The total comprehensive income for the first quarter was approximately ¥77.11 million, compared to ¥60.54 million in the same period last year[24] Cash Flow - The net cash flow from operating activities improved significantly, reaching -¥5,927,387.04, a 79.86% increase from -¥29,426,149.07 in the previous year[5] - Cash flow from operating activities showed a net outflow of approximately ¥5.93 million, an improvement from a net outflow of ¥29.43 million in Q1 2022[26] - The company reported cash inflows from investment activities of approximately ¥193.31 million, a decrease from ¥572.60 million in the same quarter last year[26] - The net cash flow from financing activities was negative at approximately ¥3.03 million, compared to a negative cash flow of ¥49.94 million in Q1 2022[27] - The company experienced a foreign exchange loss impacting cash and cash equivalents of approximately ¥2.10 million during the quarter[27] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,995,901,600.82, a 2.41% increase from ¥2,925,260,842.41 at the end of the previous year[5] - Current assets totaled ¥1,855,503,424.29 at the end of the period, an increase from ¥1,828,452,182.29 at the beginning of the year[20] - The company’s total liabilities decreased to ¥991,927,746.93 from ¥1,005,435,860.00, indicating a reduction of 1.3%[21] - Cash and cash equivalents at the end of the period were ¥814,664,022.59, down from ¥838,136,028.79 at the beginning of the year, a decrease of 2.8%[20] - Inventory increased to ¥429,391,781.06 from ¥375,902,952.82, marking a rise of 14.2%[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,048, with the largest shareholder holding 28.08% of the shares[13] - In Q1 2023, the company reported a total of 33,123,600 shares held by Guangdong Hengjian International Investment Co., accounting for 12.04% of total shares[14] - Shareholder Song Jie holds 18,633,103 shares, representing 6.77% of total shares, while Song Yong holds 11,091,800 shares, or 4.03%[14] - The company’s major shareholders include China Construction Bank with 13,500,000 shares (4.91%) and other investment funds holding significant stakes[14] - As of March 31, 2023, the total number of restricted shares held by Song Jie decreased by 5,626,650 shares, leaving 17,009,070 shares[17] Expenses and Investments - The company reported a significant increase in sales expenses, which rose by 106.97% to ¥5,487,000, primarily due to increased personnel costs and market expansion efforts[10] - The investment income increased by 27.77% to ¥831,000, attributed to higher returns from investments in Ningbo Ruiyuan[10] - The company invested ¥22,230,348.74 in R&D during Q1 2023, compared to ¥20,677,466.87 in the same period last year, showing an increase of 7.5%[23] Other Financial Metrics - The company recorded a decrease in cash flow from investing activities, which fell by 110.92% to -¥14,134,470.00, mainly due to a reduction in the redemption of financial products[11] - The company reported a net profit attributable to shareholders of ¥1,282,855,282.37, up from ¥1,205,049,756.63 at the beginning of the year, reflecting a growth of 6.4%[21] - Total operating costs for Q1 2023 were ¥261,998,562.12, up 54.5% from ¥169,474,938.59 in Q1 2022[23] - The cumulative percentage of shares held by major shareholder Song Jie and her concerted parties decreased by 5.00% during the reporting period[18] - The company announced plans to adjust the repurchase price of its 2021 and 2022 restricted stock incentive plans, pending approval at the 2022 annual shareholders' meeting[18] - The company’s financial statements for Q1 2023 are compiled as of March 31, 2023, indicating ongoing financial assessments[19]